Actavis buying Durata Therapeutics for $616.4M

SHARE Actavis buying Durata Therapeutics for $616.4M

Specialty pharmaceutical company Actavis is buying Chicago-based Durata Therapeutics Inc. for about $616.4 million to help bolster its infectious disease portfolio. One of Durata’s key products is Dalvance for injection, an IV antibiotic for acute bacterial skin and skin structure infections. Dalvance was approved by the Food and Drug Administration in May.

Read more at Newsfeed.

The Latest
Girls says the man is angry that she stood up for her mom in a disagreement about the couple’s sex and drinking habits.
Trout Unlimited’s Trout In The Classroom teaches young students about fish and the aquatic environment, capped by a day trip to get all wet.
From endorsing a new Bears’ stadium to revoking the subminimum wage, Johnson’s critics and allies examine where he and the city are going.
High doses become routine patient care even when they make patients so ill that they skip doses or stop taking the drugs. “There’s a gap in FDA’s authority that results in patients getting excess doses of a drug at excess costs,” says Dr. Mark Ratain.
Businesses and neighborhood associations in River North and nearby want the city to end the dining program because of traffic congestion, delays to first responders and other headaches caused by closing off a major street artery, a local restaurant executive writes.